Skip to main content
Clinical Trials/NCT04159129
NCT04159129
Unknown
Not Applicable

Effects of a Three-week Inpatient Pulmonary Rehabilitation Program on Walking Speed in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Interstitial Lung Diseases (ILD)

Schön Klinik Berchtesgadener Land1 site in 1 country43 target enrollmentNovember 7, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Disease, Chronic Obstructive
Sponsor
Schön Klinik Berchtesgadener Land
Enrollment
43
Locations
1
Primary Endpoint
change of maximum walking speed
Last Updated
6 years ago

Overview

Brief Summary

The aim of this study is to evaluate the effects of a three-week inpatient pulmonary rehabilitation (PR) program on the walking speed in patients with chronic obstructive (COPD) or interstitial lung disease (ILD).

Detailed Description

At most german traffic light crossings, a walking speed of 1,2m/sec is required to cross the road in time. Patients who are unable to cross the road at this speed, expose themselves to an increased level of stress and possibly the risk of accidents. Thus, they are discouraged from participating in an active social life. An UK study (Nolan et al., Thorax 2018) showed that only 10.7% of the 926 patients with moderate COPD attained a walking speed of 1.2m/sec. As PR plays a key role in the management of chronic lung diseases in order to improve patients´ exercise capacity, the aim of this study was to evaluate the PR effects on the Walking Speed in patients with COPD or ILD. The investigators hypothesize that PR improves the ability to cross the road in the appropriate time.

Registry
clinicaltrials.gov
Start Date
November 7, 2019
End Date
July 31, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Klaus Kenn

Prof. Dr. Klaus Kenn

Schön Klinik Berchtesgadener Land

Eligibility Criteria

Inclusion Criteria

  • Participation in a pulmonary Rehabilitation program (Schön Klinik BGL)
  • Indication: COPD or ILD
  • COPD; FEV1 \<50%
  • ILD: FVC \<70%
  • written informed consent

Exclusion Criteria

  • non compliance

Outcomes

Primary Outcomes

change of maximum walking speed

Time Frame: Day 1 and Day 21

assessed during a walk of 11m

Secondary Outcomes

  • Change in tension symptoms during a field walk test(Day 1 and Day 21)
  • Change in walking speed during a field walk test(Day 1 and Day 21)
  • Change in Quality of life: Chronic Respiratory Disease Questionnaire (CRQ)(Day 1 and Day 21)
  • Change of usual walking Speed(Day 1 and Day 21)
  • Change in balance(Day 1 and Day 21)
  • Change in maximum leg strength(Day 1 and Day 21)
  • Change in illness perception(Day 1 and Day 21)
  • Change of exercise capacity(Day 1 and Day 21)
  • Change of frailty (FFP)(Day 1 and Day 21)
  • Change in anxiety and Depression symptoms(Day 1 and Day 21)
  • Change in COPD-related fears on disease-specific disability(Day 1 and Day 21)

Study Sites (1)

Loading locations...

Similar Trials